Debiopharm Group - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH1154631D
- Pages: 47
- November 2018
- Total Views:1136
- Region : Europe
- GlobalData
- Equity Research Report
Details
Summary
Debiopharm Group (Debiopharm) is a biopharmaceutical company that develops biologics and small molecule drug candidates. The company's product portfolio includes eloxatin, elplat, dacotin, dacplat, decapeptyl, neo decapeptyl, trelstar, pamorelin, salvacyl and moapar, among others. It also offers services such as clinical development, manufacturing and quality assurance, regulatory services and innovative drug delivery and formulation, among others. Debiopharm targets therapy areas include colorectal cancer, ovarian cancer, breast cancer, prostate cancer and other sexual disorders, among others. The company has operations in Switzerland and Canada. Debiopharm is headquartered in Lausanne, Switzerland.
Debiopharm Group-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm Group, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm Group, Medical Devices Deals, 2012 to YTD 2018 9
Debiopharm Group, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Debiopharm Group, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 13
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 14
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 15
Venture Financing 17
ABAC Therapeutics Raises USD20 Million in Series A Financing 17
Immunexpress Raises USD 6 Million In Venture Financing 19
Biocartis Raises USD 40.5 Million In Series E Financing 20
Spinomix Raises USD 3 Million In Series A Financing 22
Biocartis Raises USD 44.7 Million In Series D Financing 23
Partnerships 25
Debiopharm Enters into Enters into Agreement with Paul Scherrer Institute 25
Debiopharm Partners with Merck and Pfizer 26
Debiopharm Enters into Distribution Agreement with Arbor Pharma 27
Debiopharm International Enters into Agreement with EORTC 28
United Labs Enters into Distribution Agreement with Debiopharm International 29
Debiopharm Enters into Agreement with Solid Biosciences 30
Debiopharm Enters into Co-Development Agreement with Nobelex Biotech 31
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 32
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 33
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 34
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 35
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 36
Licensing Agreements 37
Debiopharm International Enters into Licensing Agreement with Almac Discovery 37
Evotec Enters Into Licensing Agreement With Debiopharm 38
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 39
Debiopharm Enters Into Licensing Agreement With Yale University 40
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 41
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 42
Acquisition 43
Debiopharm To Acquire Pharma Company 43
Debiopharm Group-Key Competitors 44
Debiopharm Group-Key Employees 45
Debiopharm Group-Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47
List Of Figure
List of Figures
Debiopharm Group, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm Group, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm Group, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
Debiopharm Group, Pharmaceuticals & Healthcare, Key Facts 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm Group, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm Group, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm Group, Medical Devices Deals, 2012 to YTD 2018 9
Debiopharm Group, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 13
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 14
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 15
ABAC Therapeutics Raises USD20 Million in Series A Financing 17
Immunexpress Raises USD 6 Million In Venture Financing 19
Biocartis Raises USD 40.5 Million In Series E Financing 20
Spinomix Raises USD 3 Million In Series A Financing 22
Biocartis Raises USD 44.7 Million In Series D Financing 23
Debiopharm Enters into Enters into Agreement with Paul Scherrer Institute 25
Debiopharm Partners with Merck and Pfizer 26
Debiopharm Enters into Distribution Agreement with Arbor Pharma 27
Debiopharm International Enters into Agreement with EORTC 28
United Labs Enters into Distribution Agreement with Debiopharm International 29
Debiopharm Enters into Agreement with Solid Biosciences 30
Debiopharm Enters into Co-Development Agreement with Nobelex Biotech 31
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 32
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 33
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 34
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 35
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 36
Debiopharm International Enters into Licensing Agreement with Almac Discovery 37
Evotec Enters Into Licensing Agreement With Debiopharm 38
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 39
Debiopharm Enters Into Licensing Agreement With Yale University 40
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 41
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 42
Debiopharm To Acquire Pharma Company 43
Debiopharm Group, Key Competitors 44
Debiopharm Group, Key Employees 45
Debiopharm Group, Subsidiaries 46
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Debiopharm Group, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Debiopharm Group (Debiopharm) is a biopharmaceutical company that develops biologics and small molecule drug candidates. The company's product portfolio includes eloxatin, elplat, dacotin, dacplat, decapeptyl, neo decapeptyl, trelstar, pamorelin, salvacyl and moapar, among others. It also offers services such as clinical development, manufacturing and quality assurance, regulatory services and innovative drug delivery and formulation, among others. Debiopharm targets therapy areas include colorectal cancer, ovarian cancer, breast cancer, prostate cancer and other sexual disorders, among others. The company has operations in Switzerland and Canada. Debiopharm is headquartered in Lausanne, Switzerland.
Debiopharm Group-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm Group, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm Group, Medical Devices Deals, 2012 to YTD 2018 9
Debiopharm Group, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Debiopharm Group, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 13
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 14
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 15
Venture Financing 17
ABAC Therapeutics Raises USD20 Million in Series A Financing 17
Immunexpress Raises USD 6 Million In Venture Financing 19
Biocartis Raises USD 40.5 Million In Series E Financing 20
Spinomix Raises USD 3 Million In Series A Financing 22
Biocartis Raises USD 44.7 Million In Series D Financing 23
Partnerships 25
Debiopharm Enters into Enters into Agreement with Paul Scherrer Institute 25
Debiopharm Partners with Merck and Pfizer 26
Debiopharm Enters into Distribution Agreement with Arbor Pharma 27
Debiopharm International Enters into Agreement with EORTC 28
United Labs Enters into Distribution Agreement with Debiopharm International 29
Debiopharm Enters into Agreement with Solid Biosciences 30
Debiopharm Enters into Co-Development Agreement with Nobelex Biotech 31
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 32
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 33
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 34
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 35
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 36
Licensing Agreements 37
Debiopharm International Enters into Licensing Agreement with Almac Discovery 37
Evotec Enters Into Licensing Agreement With Debiopharm 38
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 39
Debiopharm Enters Into Licensing Agreement With Yale University 40
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 41
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 42
Acquisition 43
Debiopharm To Acquire Pharma Company 43
Debiopharm Group-Key Competitors 44
Debiopharm Group-Key Employees 45
Debiopharm Group-Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47
List Of Figure
List of Figures
Debiopharm Group, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm Group, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm Group, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
Debiopharm Group, Pharmaceuticals & Healthcare, Key Facts 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm Group, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm Group, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm Group, Medical Devices Deals, 2012 to YTD 2018 9
Debiopharm Group, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 13
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 14
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 15
ABAC Therapeutics Raises USD20 Million in Series A Financing 17
Immunexpress Raises USD 6 Million In Venture Financing 19
Biocartis Raises USD 40.5 Million In Series E Financing 20
Spinomix Raises USD 3 Million In Series A Financing 22
Biocartis Raises USD 44.7 Million In Series D Financing 23
Debiopharm Enters into Enters into Agreement with Paul Scherrer Institute 25
Debiopharm Partners with Merck and Pfizer 26
Debiopharm Enters into Distribution Agreement with Arbor Pharma 27
Debiopharm International Enters into Agreement with EORTC 28
United Labs Enters into Distribution Agreement with Debiopharm International 29
Debiopharm Enters into Agreement with Solid Biosciences 30
Debiopharm Enters into Co-Development Agreement with Nobelex Biotech 31
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 32
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 33
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 34
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 35
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 36
Debiopharm International Enters into Licensing Agreement with Almac Discovery 37
Evotec Enters Into Licensing Agreement With Debiopharm 38
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 39
Debiopharm Enters Into Licensing Agreement With Yale University 40
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 41
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 42
Debiopharm To Acquire Pharma Company 43
Debiopharm Group, Key Competitors 44
Debiopharm Group, Key Employees 45
Debiopharm Group, Subsidiaries 46
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Debiopharm Group, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020